{
    "Clinical Trial ID": "NCT01806675",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Glioblastoma Multiforme (GBM)",
        "  Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)",
        "  18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan",
        "  18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.",
        "INTERVENTION 2: ",
        "  Gynecological Cancers",
        "  Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)",
        "  18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan",
        "  18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Provides written informed consent",
        "  Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis treatment or treatment with other drugs that may alter angiogenesis",
        "  Able to remain still for duration of each imaging procedure (about one hour)",
        "Exclusion Criteria:",
        "  Pregnant or nursing",
        "  Contraindication to MRI",
        "  History of renal insufficiency (only for MRI contrast administration)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Change From Baseline in Maximum Standard Uptake Values (SUVmax)",
        "  Maximum standard uptake values (SUVmax) were assessed on the basis of position emission tomography (PET) scans using radiotracers 18F-FPPRGD2 and 18F-FDG at baseline and at regular medical care follow-up (6 to 12 weeks after initiation of treatment). The outcome is assessed as the difference in the maximum standard uptake values (SUVmax) values from baseline to follow-up for the 2 radiotracers, and will be reported for each disease type as the median with standard deviation.",
        "  Time frame: At baseline and 6 weeks",
        "Results 1: ",
        "  Arm/Group Title: Glioblastoma Multiforme (GBM)",
        "  Arm/Group Description: Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)",
        "  18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan",
        "  18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.",
        "  Overall Number of Participants Analyzed: 8",
        "  Median (Standard Deviation)",
        "  Unit of Measure: ratio  18F-FPPRGD2 PET scans: 8 participants",
        "  -0.98         (0.98)",
        "  18F-FDG PET scans: 0 participants",
        "Results 2: ",
        "  Arm/Group Title: Gynecological Cancers",
        "  Arm/Group Description: Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)",
        "  18F-fludeoxyglucose (18F-FDG): 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan",
        "  18F-FPPRGD2: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.",
        "  Overall Number of Participants Analyzed: 4",
        "  Median (Standard Deviation)",
        "  Unit of Measure: ratio  18F-FPPRGD2 PET scans: 4 participants",
        "  0.09         (1.20)",
        "  18F-FDG PET scans: 4 participants",
        "  -1.90         (2.80)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/11 (9.09%)",
        "  Diarrhea 20/11 (0.00%)",
        "  Vomiting 0/11 (0.00%)",
        "  Death NOS 1/11 (9.09%)",
        "Adverse Events 2:",
        "  Total: 0/6 (0.00%)",
        "  Diarrhea 20/6 (0.00%)",
        "  Vomiting 0/6 (0.00%)",
        "  Death NOS 0/6 (0.00%)"
    ]
}